(Alliance News) - Ulisse Biomed Spa and Ikonisys SA, a company specializing in the early and accurate diagnosis of cancer through a unique and fully automated solution for medical testing laboratories, announced Thursday that they have entered into a strategic collaboration to enhance their technical and commercial capabilities in oncology diagnostics.

A key aspect of this collaboration is the integration of UBM's expertise in molecular biology with Ikonisys' Liquid Cytology and Fluorescence In Situ Hybridization technology. This integration is intended to provide innovative oncology diagnostics, offering comprehensive and accurate diagnostic capabilities that can greatly improve patient outcomes.

Under this partnership, the two companies will explore cross-selling and co-marketing opportunities through their sales networks to maximize market penetration and exploit product and service synergies. In a second phase, a mutual distribution agreement will be established.

Ikonisys and UBM are committed to working together to explore and develop new business opportunities. This partnership reflects the shared goal to innovate and grow by combining skills and resources. Therefore, an in-depth technical discussion will also be conducted to discuss potential manufacturing and OEM agreements, with the goal of optimizing manufacturing techniques and ensuring high product quality. The initiative will integrate the technical expertise of both companies, promoting innovative and competitive solutions in oncology diagnostics.

The partnership will first take place with mutual installation and training of instruments at Hospitex Lab in Florence, part of the Ikonisys Group, scheduled for late June to mid-July. Through this cooperation, the companies will be able to familiarize themselves with each other's technologies and expertise, fostering closer technical cooperation.

Ulysses Biomed's stock on Thursday closed up 0.9 percent at EUR1.13 per share.

By Giuseppe Fabio Ciccomascolo, Alliance News senior reporter

Comments and questions to redazione@alliancenews.com

Copyright 2024 Alliance News IS Italian Service Ltd. All rights reserved.